FDA 483 - Bio-Thera Solutions, Ltd. - September 26, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Bio-Thera Solutions, Ltd. in Guangzhou, China, revealed significant deficiencies in their drug substance and drug product manufacturing operations. The firm failed to establish and follow adequate procedures for production controls, media fill validation, and visible particle prevention. Additionally, the Quality Unit's responsibilities were found to be inadequate, and the firm demonstrated a failure to thoroughly investigate discrepancies and ensure proper laboratory instrument qualification.
ID · 1291a665-3a01-4621-83d3-f5390764690e